BLUEPRINT for a Sustainable Supply of Prescription Medicines
A CAPDM Webinar: October 21, 2020, 2:00 PM - 3:00 PM
Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), will review key strategies to reach a sustainable supply of prescription medicines for Canadians.
CGPA is encouraged by the renewed focus of governments on enhancing the capacity of the Canadian prescription drug industry and increasing its domestic capabilities. It is possible to strengthen Canada's existing pharmaceutical manufacturing capacity, promote a well-functioning global supply chain, and adopt a coordinated approach to better equip Canada for future health emergencies, such as the ongoing global COVID-19 pandemic, by focusing on the following three key areas:
- Strengthening Canada’s Domestic Pharmaceutical Industry
- Securing and Enhancing Canada’s Role in the International Pharmaceutical Supply Chain
- Identifying Essential Generic Medicines to Domestically Produce and Stockpile for Canadian Needs
Jim Keon, President, CGPA
Under Jim’s leadership, the CGPA works closely with all levels of government to develop policies to nurture and develop Canada’s drug industry both in Canada and for export markets.
He also works closely with provincial governments to help them control soaring drug costs through the more efficient listing of generic medicines on provincial drug plan formularies.
Prior to joining CGPA (he became President in 1998) he was directly involved in international trade negotiations for the FTA, NAFTA and the WTO, as well as Canada’s inter-provincial trade negotiations.
Jim is Chair of the International Generic and Biosimilar Medicines Association (IGBA).
Jim graduated with an M.A. in Economics from Queen’s University, and has extensive experience in areas of intellectual property, trade and consumer protection.
*There is no cost to attend.
